Basis: Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The EBITDA yield is N/A as of 2026-10-06T22:43:41.522Z.
Calculation as of: 2026-10-06T22:43:41.522Z.
Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: b864e21534e19d3622fdd1df0bfa06a86802ee3b4002ae0b13a65066f94ec11b
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EBITDA YIELD
N/A
Market Cap
$2.06B
EBITDA Yield
N/A
TTM Avg
1.31%
3Y Avg
2.16%
5Y Avg
2.16%
Market Cap
$2.02B
EBITDA Yield
N/A
TTM Avg
4.83%
3Y Avg
4.83%
5Y Avg
4.83%
Market Cap
$2.11B
EBITDA Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$2.02B
EBITDA Yield
8.96%
TTM Avg
5.82%
3Y Avg
4.86%
5Y Avg
4.86%
| NAME | MARKET CAP | EBITDA YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Viridian Therapeutics, Inc. (VRDN) | $2.06B | N/A | N/A | N/A | N/A |
| Celldex Therapeutics, Inc. (CLDX)vs › | $2.06B | N/A | 1.31% | 2.16% | 2.16% |
| Alvotech (ALVO)vs › | $2.08B | 2.38% | 3.21% | 2.55% | 2.55% |
| Vericel Corporation (VCEL)vs › | $2.05B | 1.54% | 1.16% | 0.60% | 0.56% |
| Progyny, Inc. (PGNY)vs › | $2.03B | 6.27% | 5.01% | 3.79% | 2.59% |
| BioCryst Pharmaceuticals, Inc. (BCRX)vs › | $2.02B | N/A | 4.83% | 4.83% | 4.83% |
| SELLAS Life Sciences Group, Inc. (SLS)vs › | $2.11B | N/A | N/A | N/A | N/A |
| UroGen Pharma Ltd. (URGN)vs › | $2.02B | N/A | 1.16% | 1.16% | 1.16% |
| Aurinia Pharmaceuticals Inc. (AUPH)vs › | $2.02B | 8.96% | 5.82% | 4.86% | 4.86% |
| Vera Therapeutics, Inc. (VERA)vs › | $2.11B | N/A | N/A | N/A | N/A |
EBITDA Yield = TTM EBITDA / Enterprise Value
EBITDA yield is the inverse of EV/EBITDA, expressing trailing pre-interest, pre-tax operating cash generation as a percentage of enterprise value. Comparable across leverage levels; higher is cheaper. Not meaningful for banks and insurers.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
